Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens

FEMS Immunology and Medical Microbiology
Brian R SloatZhengrong Cui

Abstract

A new generation anthrax vaccine is expected to target not only the anthrax protective antigen (PA) protein, but also other virulent factors of Bacillus anthracis. It is also expected to be amenable for rapid mass immunization of a large number of people. This study aimed to address these needs by designing a prototypic triantigen nasal anthrax vaccine candidate that contained a truncated PA (rPA63), the anthrax lethal factor (LF), and the capsular poly-gamma-D-glutamic acid (gammaDPGA) as the antigens and a synthetic double-stranded RNA (dsRNA), polyriboinosinic-polyribocytodylic acid (poly(I:C)) as the adjuvant. This study identified the optimal dose of nasal poly(I:C) in mice, demonstrated that nasal immunization of mice with the LF was capable of inducing functional anti-LF antibodies (Abs), and showed that nasal immunization of mice with the prototypic triantigen vaccine candidate induced strong immune responses against all three antigens. The immune responses protected macrophages against an anthrax lethal toxin challenge in vitro and enabled the immunized mice to survive a lethal dose of anthrax lethal toxin challenge in vivo. The anti-PGA Abs were shown to have complement-mediated bacteriolytic activity. After further o...Continue Reading

References

Dec 11, 1976·Journal of the National Cancer Institute·C J CornellO R McIntyre
Mar 11, 1992·Journal of General Microbiology·J W Ezzell, T G Abshire
Mar 1, 1988·European Journal of Epidemiology·B E Ivins, S L Welkos
Oct 6, 1997·Journal of Dairy Science·S C FeijooJ H Martin
Sep 4, 1999·Journal of Applied Microbiology·A M Friedlander
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Nov 9, 2001·Nature·K A BradleyJ A Young
May 1, 2002·JAMA : the Journal of the American Medical Association·Thomas V InglesbyUNKNOWN Working Group on Civilian Biodefense
May 7, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Zhengrong Cui, Russell J Mumper
Nov 19, 2002·FEBS Letters·Paolo AscenziCesare Montecucco
Apr 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Heather M ScobieJohn A T Young
May 22, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Prosper N BoyakaJerry R McGhee
Jul 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Rachel SchneersonJohn B Robbins
Sep 10, 2003·Proceedings of the National Academy of Sciences of the United States of America·Gi-Eun RhieJulia Y Wang
Sep 23, 2003·Nature Immunology·Agnes Le BonDavid F Tough
Mar 31, 2004·Proceedings of the National Academy of Sciences of the United States of America·Thomas R KozelC Rick Lyons
Apr 8, 2004·Vaccine·Darrell GallowayJames Estep
Jul 9, 2004·The Journal of Allergy and Clinical Immunology·Marianna KulkaDean D Metcalfe
Sep 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·G HermansonP Hobart
Nov 3, 2004·Vaccine·Donald J ChabotArthur M Friedlander
Feb 8, 2005·Current Opinion in Microbiology·Heather M Scobie, John A T Young
Feb 16, 2005·Nature·Oliver SchulzCaetano Reis e Sousa

❮ Previous
Next ❯

Citations

Aug 18, 2010·Antimicrobial Agents and Chemotherapy·Gaobing WuZiduo Liu
Mar 30, 2011·BMC Cancer·B Leticia RodriguezZhengrong Cui
Feb 11, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Akhilesh Kumar ShakyaHarvinder Singh Gill
Jan 28, 2010·Journal of Medicinal Chemistry·Dimitrios G Bouzianas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Related Papers

Clinical and Vaccine Immunology : CVI
Qingfu Xu, Mingtao Zeng
Proceedings of the National Academy of Sciences of the United States of America
Christine TrumpfhellerRalph M Steinman
Proceedings of the National Academy of Sciences of the United States of America
Gi-Eun RhieJulia Y Wang
© 2021 Meta ULC. All rights reserved